Liver Disease in Urea Cycle Disorders

Status Recruiting

Clinical Trial Summary

This is a multi-center, cross-sectional study to assess risk for liver fibrosis and hepatic injury in individuals with urea cycle disorders (UCDs) using serum biomarkers, Fibroscan, and MRE. This study will be conducted at 5 sites of the Urea Cycle Disorders Consortium: Baylor College of Medicine in Houston, TX, Seattle Children's Hospital in Seattle, WA, Children's Hospital Colorado in Aurora, CO, Children's Hospital of Philadelphia in Philadelphia, PA, and Children's National Medical Center in Washington D.C.

Clinical Trial Description

Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With early diagnosis and improved treatments, the survival of individuals with UCDs has improved, and this improved survival has led to unmasking of some long-term complications such as hepatic dysfunction and progressive fibrosis in a subset of patients. Hepatic complications in UCDs are quite variable and dependent upon the specific metabolic defect. Currently, there are no guidelines for monitoring hepatic complications or extent of liver disease in UCDs. The gold standard for staging of fibrosis or confirming cirrhosis has traditionally been liver biopsy, an invasive procedure with inherent risks, particularly in the setting of a UCD and compromised coagulation. Recently, non-invasive serum and imaging-based biomarkers have been introduced to assess hepatic fibrosis in adults and children who are at increased risk. Utilization of these technique in individuals with UCDs could be invaluable in both the research and clinical arenas. The purpose of this study is: 1) To assess risk for increased fibrosis using serum biomarkers and/or VCTE in distal disorders (ASS1D, ASLD and ARG1D) as compared to OTCD 2 ) To assess risk for hepatic fibrosis (liver stiffness as measured by MRE) in individuals with UCDs who have abnormal serum biomarkers and/or VCTE as those who have normal values ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04612764
Study type	Observational
Source	Baylor College of Medicine
Contact	Saima Ali, MSN
Phone	832-822-4183
Email	saima.ali@bcm.edu
Status	Recruiting
Phase
Start date	November 4, 2021
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01948427` - Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)
Terminated	`NCT03933410` - UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder	Phase 2
Completed	`NCT03064048` - Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	N/A
Completed	`NCT05330039` - Characterization of Intestinal Microbiota in Children With Inborn Errors of Metabolism (IEM)
Completed	`NCT03721367` - Chronic Liver Disease in Urea Cycle Disorders
Completed	`NCT03911089` - A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD	N/A
Terminated	`NCT03181828` - Manipulating the Gut Microbiome Study	Phase 1/Phase 2
Completed	`NCT00472732` - Neurologic Injuries in Adults With Urea Cycle Disorders	N/A
Recruiting	`NCT05076318` - Dysregulated Urea-synthesis at Terminal Uremia	N/A
Completed	`NCT03179878` - Safety and Tolerability of SYNB1020-CP-001	Phase 1
Recruiting	`NCT04602325` - Systemic Biomarkers of Brain Injury From Hyperammonemia
Withdrawn	`NCT03884959` - A Safety and Efficacy Study of Infusions of HepaStem in Urea Cycle Disorders Pediatric Patients	Phase 2
Recruiting	`NCT04908319` - Hepatic Histopathology in Urea Cycle Disorders
Completed	`NCT03335488` - Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)	Phase 4
Completed	`NCT02246218` - A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders	Phase 4
Completed	`NCT04248062` - Patient and Observer Reported Outcome Measurements in Inborn Errors of Metabolism
Completed	`NCT05706714` - Th1, Th2, Th17 Phenotype in Urea Cycle Disorders
Enrolling by invitation	`NCT03343756` - HepaStem Long-Term Safety Registry

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.